RITM Australia Pty Ltd
Unit 4, 130-137 Pacific Hwy
Greenwich NSW 2065
PO Box 843
Lane Cove NSW 1595
Australia

ABN: 26 125 344 952

Tel: 02 8011 4217
Fax: 02 9439 1930

www.ritmscenar.com.au
info@ritmscenar.com.au

ACN: 125 344 952

SCENAR THERAPY APPLICATIONS

Shvanke I., Antonova T., Tarakanov A., Rostov-on-Don, Russia

Using The SCENAR-Therapy At Glaucoma

"Glaucoma" unites a large group of diseases with a predominantly chronic development and grave prognosis. We might note its considerable diffusion, the great variety of clinical forms, the difficulties of the early diagnostics and treatment. The glaucoma affects people in able-bodied age. The frequency of blindness from glaucoma in our and other developed countries keeps a steady high level.

There were observed 15 patients with primary wide-angle glaucoma (n=7), secondary (phacomorphic and traumatic, n=8). Age of the patients – 42-72 years, (men – 10, women – 5). The treatment was conducted at rather late and terminal phases of the disease in pre- and postoperative period. The patients were operated on: sinustrabecuectomia (STEK) and extra capsule extraction of the cataract with implantation of ocular lens (EEC+IOL).

The influence was accomplished in permanent, individually dozed and modulated regimes while taking into account the indications of the little asymmetry every day or every other day; the quantity of the procedures- from 5 to 10. The methodics of treatment was chosen individually, depending on concomitant diseases and peculiarities of the pathological process from the aspect of the eyes.

The influence was accomplished in the periorbital region, the area of the outlet of the trigeminal and facial nerves, the retro occipital neck zone and in the area of projection of the liver and of the whole spinal column. Criteria for an estimate of the results: increase of the acuteness of visin, objective examination of the ocular organs, tonometry, and laboratory and immunologic findings.

It was observed that in the cases of primary glaucoma the acuteness of visin before and after the treatment practically did not change, which is explained by the gravity of circular and trophic disorders, the full atrophy of the ophthalmic nerve. In the cases of secondary glaucoma (phacomorphic) the acuteness of visin in comparison with the check group proved to be a little higher. The greatness of the intraocular pressure decreased considerably at the end of the treatment, particularly sharply in the postoperative period. The findings of the objective examination showed that the treatment helped for conducting more efficient preoperative preparation, improvement of the vascularity in the back part of the eye, anesthesia in the postoperative period.

Results

The SCENAR therapy appears an effective method for complex treatment of the glaucoma; it is necessary to take into consideration the stage of development of the process; the treatment to be conducted extremely carefully with no heavy strain; in the process of treatment it is possible to have an increase of the intraocular pressure; it is necessary to repeat this course of treatment.

The information in this document is provided by RITM OKB ZAO, Taganrog, Russian Federation

SCENAR TECHNOLOGY OVERVIEW

The name SCENAR derives from: **Self-Controlled Energo-Neuro-Adaptive Regulation.**

The SCENAR is an electronic-therapy device invented by a team of Russian Scientists (Alexander Karasev and Prof. Revenko) and developed further by RITM OKB ZAO in the 1980's for use in space, where cosmonauts would have a means of treating themselves in orbit, without the need to take drugs.

RITM OKB ZAO in the only manufacturer of the original SCENAR technology.

RITM OKB ZAO now has set up a branch in Australia - RITM Australia to provide local support for their products - SCENAR devices for Professionals and Home user and Healing Blankets.

RITM SCENAR devices are CE Mark certified (the highest standard for manufacturing medical devices in the world), ISO 9001, ISO 13845.

RITM SCENAR devices are also included in the Australian Register for Therapeutic Goods Administration under TGA # 140659.

At present the SCENAR medical devices have been recognized in 60 countries all over the world: the United Kingdom, Australia, New Zealand, the Netherlands, Austria, Germany, Italy, Israel, Hungary, Czech Republic, Turkey, South Korea, the US, etc.

Over 6,000 doctors are now using the Scenar as an integral part of their medical practice.

The product range includes professional devices and devices for home users and sportsman, Healing Blankets and accesories.

	Professional series SCENAR devices – for medical practitioners and therapists
	Home SCENAR device series – sportsmen and personal home use
	**OLM** Healing Blankets and their modifications